X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for the treatment of EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.
Lead Product(s): HS-20117
Therapeutic Area: Oncology Product Name: PM1080
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Biotheus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 15, 2024
Details:
Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload, in advanced solid tumours.
Lead Product(s): HS-20093
Therapeutic Area: Oncology Product Name: HS-20093
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $1,710.0 million Upfront Cash: $185.0 million
Deal Type: Licensing Agreement December 20, 2023
Details:
Under the agreement, GSK will obtain rights to progress development and commercialisation for HS-20089, a B7-H4 targeted antibody-drug conjugate currently in phase I clinical trials in China, in ovarian and endometrial cancer.
Lead Product(s): HS-20089
Therapeutic Area: Oncology Product Name: HS-20089
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $1,570.0 million Upfront Cash: $85.0 million
Deal Type: Licensing Agreement October 20, 2023
Details:
Under the agreement, Hansoh will be exclusively responsible for commercialization of Xpovio (selinexor), world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1, in the mainland of China for relapsed or refractory multiple myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Antengene
Deal Size: $101.5 million Upfront Cash: $27.6 million
Deal Type: Collaboration August 10, 2023
Details:
Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Scynexis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.
Lead Product(s): siRNA
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Silence Therapeutics
Deal Size: $1,316.0 million Upfront Cash: $16.0 million
Deal Type: Collaboration July 11, 2023
Details:
TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.
Lead Product(s): HS-10518
Therapeutic Area: Neurology Product Name: TU2670
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Tiumbio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.
Lead Product(s): Aumolertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Ameile
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Under the terms of the agreement, Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.
Lead Product(s): NKT2152
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: NiKang Therapeutics
Deal Size: $218.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration May 03, 2022
Details:
Silence and Hansoh entered a collaboration to develop siRNAs leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the rest two targets in all territories except the China region.
Lead Product(s): SLN-HAN-1
Therapeutic Area: Technology Product Name: SLN-HAN-1
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Silence Therapeutics
Deal Size: $1,316.0 million Upfront Cash: $16.0 million
Deal Type: Collaboration April 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
